10-KPeriod: FY2022

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2022

Filed February 16, 2023For Securities:IDXX

Summary

IDEXX Laboratories Inc. reported solid revenue growth of 4.7% to $3.37 billion for the fiscal year ended December 31, 2022. This growth was primarily driven by the Companion Animal Group (CAG), which saw an 8.4% organic revenue increase, demonstrating continued demand for veterinary diagnostics and services. Despite a slight decrease in clinical visits, revenue per practice grew, highlighting increased utilization of diagnostic products. The Water segment also showed positive organic growth of 9.7%. However, the Livestock, Poultry, and Dairy (LPD) segment experienced a decline, largely due to reduced demand in China for swine testing. Research and development expenses saw a significant increase (58.3%) due to strategic investments in technology licensing. The company highlighted its strong gross profit margin of 59.5%, supported by price gains and efficiency initiatives, though facing increased costs in freight, distribution, and labor. IDEXX also actively managed its capital through share repurchases and a $1.25 billion credit facility, ending the year with $112.5 million in cash and cash equivalents. The company remains focused on innovation, customer relationships, and operational efficiency to navigate a competitive landscape and maintain long-term value creation for shareholders.

Financial Highlights

54 data points
Beta

Revenue

$3.37B

59.5% Gross Margin

Net Income

$679.09M

20.2% Net Margin

EPS (Diluted)

$8.03

Total Assets

$2.75B

Cash & Equivalents

$112.55M

Free Cash Flow

$394.15M

Financial Statements
Beta
Revenue$3.37B
Cost of Revenue$1.36B
Gross Profit$2.00B
R&D Expenses$254.82M
Operating Expenses$1.11B
Operating Income$898.76M
Interest Expense$39.86M
Net Income$679.09M
EPS (Basic)$8.12
EPS (Diluted)$8.03
Shares Outstanding (Basic)83.62M
Shares Outstanding (Diluted)84.60M

Key Highlights

  • 1IDEXX Laboratories reported total revenue of $3.37 billion for fiscal year 2022, a 4.7% increase year-over-year.
  • 2The Companion Animal Group (CAG) was the primary growth driver, with organic revenue increasing by 8.4%, showcasing continued strong demand in the veterinary diagnostics market.
  • 3Gross profit margin remained robust at 59.5%, an improvement from the previous year, driven by price increases and operational efficiencies, although tempered by rising freight, distribution, and labor costs.
  • 4Research and Development (R&D) expenses increased significantly by 58.3% to $254.8 million, reflecting strategic investments in technology and innovation.
  • 5The company maintained a strong balance sheet, ending the year with $112.5 million in cash and cash equivalents and access to a $1.25 billion credit facility.
  • 6The Livestock, Poultry, and Dairy (LPD) segment experienced a revenue decline of 9.8%, primarily attributed to decreased demand for swine testing in China.
  • 7IDEXX actively engaged in share repurchases, buying back approximately 2.0 million shares during the fiscal year 2022.

Frequently Asked Questions

IDEXX Laboratories reported a total revenue of $3.37 billion for the fiscal year ended December 31, 2022, representing a 4.7% increase compared to the previous year. The company maintained a healthy gross profit margin of 59.5%, demonstrating strong operational efficiency and pricing power, although it also faced increased operating expenses related to sales, marketing, and R&D investments.

The Companion Animal Group (CAG) was the primary growth engine, with an organic revenue increase of 8.4%, driven by strong demand for diagnostics and services. The Water segment also performed well with 9.7% organic revenue growth. However, the Livestock, Poultry, and Dairy (LPD) segment saw a revenue decline of 9.8%, mainly due to reduced demand for swine testing in China. The 'Other' segment also declined significantly due to decreased sales of COVID-19 testing products.

IDEXX strategically increased its investment in Research and Development (R&D) by 58.3% to $254.8 million, focusing on technology licensing and innovation. The company also actively managed its capital structure through share repurchases and utilized its $1.25 billion credit facility, ending the year with $112.5 million in cash and cash equivalents. The company's leverage ratio remained well within covenant limits, indicating a stable financial position.

IDEXX faces several risks including intense competition in the companion animal diagnostics market, potential supply chain disruptions and rising costs due to inflation, foreign currency exchange rate fluctuations, and evolving government regulations. The company also notes the potential impact of economic downturns on customer spending and increased consolidation among veterinary practices.